#ESMO26 Dr. Li Zhang presents PANKU-Lung01: phase III izalontamab brengitecan (iza-bren, HER3:EGFR ADC) vs platinum based chemo in EGFR+ NSCLC after 3G TKI. Iza bren improved PFS: 11.1 vs 5.7m, HR 0.40! OS immature but 1y rates 83% vs 73%. High reduction/interruption rates but low discontinuation rates. Most common toxicities were hematologic in nature. Very exciting data here: ADCs here to stay. #ESMOAmbassadors
196 views · 5 likes · 3 reposts · 0 replies
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgPANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Stephen V Liu, MD · x.com